Comparison 3. Serious adverse events.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Risk of serious adverse events compared with placebo by drug	10		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1.1 Avoralstat	1	48	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.80]
3.1.2 Berotralstat	3	128	Risk Ratio (M‐H, Random, 95% CI)	0.77 [0.02, 24.03]
3.1.3 C1‐INH‐nf	1	48	Risk Ratio (M‐H, Random, 95% CI)	Not estimable
3.1.4 C1‐INH(SC)	1	87	Risk Ratio (M‐H, Random, 95% CI)	0.34 [0.01, 8.14]
3.1.5 pdC1‐INH	1	128	Risk Ratio (M‐H, Random, 95% CI)	0.54 [0.09, 3.10]
3.1.6 rhC1‐INH	1	86	Risk Ratio (M‐H, Random, 95% CI)	1.50 [0.06, 34.66]
3.1.7 Lanadelumab	2	162	Risk Ratio (M‐H, Random, 95% CI)	0.88 [0.08, 10.39]
3.2 Risk of serious adverse events – head‐to‐head trials	2		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.2.1 Short‐term trials	1	86	Risk Ratio (M‐H, Random, 95% CI)	0.33 [0.01, 7.96]
3.2.2 Long‐term trials	1	133	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.32, 4.01]